View Risk


Article data
Gao (2020)
Prognostic value of NT-proBNP in patients with severe COVID-19
32293449
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156898/

Results
Laboratory Findings
Lymphocytes (1 unit increase vs. Not applicable)
COVID-19 (death)
Hazard ratio: 0.160 (0.040-0.760) Adjusted model

Study characteristics

China

Retrospective cohort study

Medical records

102

The study initially enrolled 102 patients with severe COVID-19 from a continuous sample in Hubei General Hospital during the management by national medical team. After screening out the ineligible cases, 54 patients were analyzed in this study.

Study demonstrated that the heart failure marker, N terminal pro B type natriuretic peptide (NT-proBNP), increased significantly during the course of hospitalization in those who ultimately died. However, there is no research concerning whether NT-proBNP predicted the outcome of severe COVID-19 patients.

Total

15 Day


Results

COVID-19 (death)

54

54 patients with COVID-19 were studied in this research. NT-proBNP might be an independent risk factor for in-hospital death in patients with severe COVID-19.

Laboratory Findings

Lymphocytes

LYM, per 1×10^9/L. Patients in NT-proBNP high group were significantly higher levels of lymphocytes (LYM)

Not applicable

1 unit increase

Hazard ratio

0.160 (0.040-0.760)

Yes

No

Yes

NT-proBNP, WBC and LYM (Mode 5)


Other information

NT-proBNP might be an independent risk factor for in-hospital death in patients with severe COVID-19. Relationship between plasma NT-proBNP level and the risk of in-hospital death in severe COVID-19 patRents. Severe COVID-19 patients with high NT-proBNP levels tended to be older with increased cardiac injury markers and higher levels of systematic inflammation markers.

Good

Yes

Go Back